From all over the nation hundreds of families filed lawsuits against Zofran the manufacturers (GlaxoSmithKline) of Zofran and more than 200 are in the multidistrict litigation court. Ondansetron, popularly known as Zofran is a medication used to prevent and reduce chemotherapy and surgery related nausea and vomiting. Despite Zofran has shown effectiveness in treating nausea and vomiting in pregnancy, according to several studies and trials which demonstrate that it also comes with serious side effects to both mother and infant, the FDA has cautioned against its use in pregnancy and given an rating of Pregnancy Category B which indicates that the medication has not been proven safe for uses in pregnancy but Doctors continue to prescribe nausea drug Zofran to pregnant women despite the adverse effect of the drug. According to a new study which reveals that there is no evidence to support a substantial increased risk of birth defects associated with Zofran.
Zofran is designed to cure vomiting and morning sickness in pregnant women. It blocks the actions of chemicals in the body that can trigger nausea and vomiting. Zofran is manufactured and sold by GlaxoSmithKline and it is available as an oral tablet (ondansetron hydrochloride), oral solution and oral disintegrating tablet and as an injection for intravenous use. According to a new research led by Marlena Fejzo of the UCLA Department of Medicine and published in the journal Reproductive Toxicology, did not find link between the popular nausea drug Zofran and birth defects. She stated that the study confirmed that instead of birth defects women who took Zofran were less likely to have a miscarriage or a stillbirth. Although Zofran has never been approved for pregnant woman but the study conclude that Zofran medication can stop nausea and vomiting which led a mother to give birth a healthy baby.
The recent study once again raise the controversial question that whether Zofran is safe to take during pregnancy or not. Many studies have found a 30% increased risk of birth defects, a doubled risk of “hole in the heart” defects, heart rhythm disorders and even higher rates of cleft lip and cleft palate. A 2011 study performed by a grant from the Centers for Disease Control and Prevention (CDC) states that Zofran doubles the risks of birth defects, the risk of developing congenital heart defects in particular significantly higher, including: 8 times higher risk of developing atrioventricular septal defects, 3 times higher risk of developing ventricular septal defects and 1 times higher risk of developing atrial septal defects. Until more research and studies are undertaken, it is unclear of the percentage of infants that may have birth defects associated with Zofran.
Several studies and research linking Zofran association with a potential risk of birth defects has been growing for years, which accumulates evidence to lawsuits. The lawsuits against the manufacturer alleges that GlaxoSmithKline fails to warn patients of the risks associated with Zofran medication, the drug is not properly tested before going to market and manufacturer negligence for safety. Any woman who was prescribed Zofran during pregnancy and suffered from birth defects like congenital heart defects, Webbed Toes, Kidney malformation or any other birth defects contact Drugsclaim.com for free and confidential case review.